Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $32.50

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received an average rating of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $32.29.

Several equities research analysts recently commented on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird boosted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $24.23 on Monday. The firm has a market cap of $2.94 billion, a PE ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84. The firm has a fifty day moving average of $22.39 and a 200 day moving average of $21.61. Catalyst Pharmaceuticals has a one year low of $14.47 and a one year high of $24.64.

Insider Activity

In other news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth about $65,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.